Medical Humanities
March 30, 2018
Lucas Richert, Matthew DeCloedt
4 citations
Much discussion about mental health has revolved around treatment models. As interdisciplinary scholarship has shown, mental health knowledge, far from being a neutral product detached from the society that generated it, was shaped by politics, economics and culture. By drawing on case studies of yoga, religion and fitness, this article will examine the ways in which mental health...
Psychopharmacology
November 20, 2017
Allison A. Feduccia, Julie Holland, Michael C Mithoefer
79 citations
Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD), but does not provide definitive treatment, and side effects of daily medication are often problematic. Trauma-focused psychotherapies are more likely than drug treatment to achieve PTSD remission, but have high dropout rates and ineffective for a large percentage of patients. Therefore, research into drugs...
Psychopharmacology
November 8, 2017
R. L. Carhart-Harris, Mark Bolstridge, C. M. J. Day et al.
978 citations
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major...
Performance Research
August 18, 2017
Richard Talbot
2 citations
Give Me Your Love by Jon Haynes and David Woods, Artistic Directors of Ridiculusmus, is the second in a trilogy Dialogue As The Embodiment of Love, to be presented in 2018, a series of plays investigating innovative mental health therapies. Give Me Your Love is a response to the first UK trials of MDMA assisted psychotherapy for chronic treatment resistant PTSD. The work has been made in...
Journal of Humanistic Psychology
June 19, 2017
Rosalind Watts, Camilla Day, Jacob Krzanowski et al.
582 citations
Objective: To identify patients’ perceptions of the value of psilocybin as a treatment for depression. Method: Twenty patients enrolled in an open-label trial of psilocybin for treatment-resistant depression participated in a semistructured interview at 6-month follow-up. Thematic analysis was used to identify patients’ experiences of the treatment and how it compared with previous treatments....
Neuropsychopharmacology
April 26, 2017
Robin Carhart-Harris, Guy M. Goodwin
680 citations
Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before...
Journal of Psychoactive Drugs
2017
Annamarie Heink, Steve Katsikas, Tiffany Lange-Altman
35 citations
Psychedelic drugs have historically been used for ritualistic purposes and to help individuals gain insight. Ibogaine, a naturally occurring psychoactive substance, has been reported to have anti-addictive properties that aid in the treatment of substance use disorders. An online survey obtained retrospective data from individuals who used ibogaine in the past. Individuals who used ibogaine...
The Lancet Psychiatry
April 5, 2016
Michael C Mithoefer, Charles S. Grob, Timothy D Brewerton
237 citations
4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as...
The British Journal of Psychiatry
2015
Ben Sessa, David Nutt
36 citations
From its first use 3,4,-methylenedioxymethamphetamine (MDMA) has been recognised as a drug with therapeutic potential. Research on its clinical utility stopped when it entered the recreational drug scene but has slowly resurrected in the past decade. Currently there is enough evidence for MDMA to be removed from its Schedule 1 status of 'no medical use' and moved into Schedule 2 (alongside...
Journal of Psychoactive Drugs
2014
Amy Emerson, Linnae Ponté, Lisa Jerome et al.
64 citations
This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity's future would be aided by the therapeutic and spiritual potential of psychedelic substances. The article traces the trajectory of MAPS from inception in 1986 to its present, noting future goals with respect to research, outreach, and harm reduction. MAPS...